A trend toward shorter OS was observed in patients with TP53 mutations compared with those without (median OS, 53 vs 76.9 months; P = .2), although this difference did not reach statistical significance, likely because of limited sample size.
← all excerpts
Clinical correlation and prognostic impact of cytogenetic clone size for myelodysplastic syndromes/neoplasm.
1
—
—